Activation of LXR-α can result in the development of hepatic steatosis, which is mediated by the hepatic lipogenic pathway, primarily through SREBP-1c, causing hepatic steatosis and hyperlipidemia. This evidence concerns the gene SREBF1 and fatty liver disease.